ADS DIAGNOSTIC LIMITED

HOLOGIC®
THE SCIENCE OF SURE

ADS/BSE/2026-27/08/06
13th August, 2026

To,
The General Manager
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street Mumbai, Maharashtra – 400 001

Sub- Outcome of the Board Meeting for the quarter ended June 30, 2023 - SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015Company Code – 523031

Dear Sir,

Pursuant to the provisions of Regulation 33 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR'), we wish to inform you that the Board of Directors (the 'Board') of ADS Diagnostic Limited ('the Company') at its meeting held today i.e. Thursday, August 13th, 2026 considered and approved the Unaudited Standalone Financial Results of the Company for the quarter ended 30th June, 2026.

The Board Meeting commenced at 12:05 p.m. and concluded at 13:10 p.m

Thanking You
Yours Faithfully

ADS Diagnostic Limited
ADS
114, Sant Nagar East of Kailash New Delhi-110065

N.L. Gayari
CFO & Company Secretary

ADS DIAGNOSTIC LIMITED

HOLOGIC®
THE SCIENCE OF SURE

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 30.06.2026

(Rs. In Lakhs)

	PARTICULARS	Quarter Ended			Year Ended
		30.06.2026	30.06.2025	31.03.2026	31.03.2026
		Unaudited	Unaudited	Audited	Audited
1	**Income from Operations**				
a)	Revenue from Operations (Net)	328.21	426.68	400.30	2,835.75
b)	Other Operating Income	23.33	13.36	3.68	13.26
	Total Income (a+b)	**351.54**	**440.04**	**403.98**	**2,849.01**
2	**Expenses**				
a)	Cost of materials Consumed	47.19	222.18	191.45	1,657.58
b)	Employee benefits expense	74.38	68.38	84.52	321.70
c)	Depreciation and amortisation expense	1.29	2.84	(1.75)	5.75
d)	Finance costs	10.27	11.91	13.45	61.12
e)	Other expenses	214.38	114.69	99.23	658.29
	Total expenses (a+b+c+d+e)	**347.51**	**420.00**	**386.90**	**2,704.44**
3	**Profit / (loss) before Tax and Exceptional Items (1-2)**	**4.03**	**20.04**	**17.08**	**144.57**
a)	**Execeptional Item**	-	-	-	-
4	**Profit / (loss) before Tax**	**4.03**	**20.04**	**17.08**	**144.57**
5	**Tax expenses**				
a)	Current Income Tax	0.81	5.27	3.74	35.83
b)	Income Tax - Earlier Years	-	-	-	-
c)	Deferred tax charge	-	-	1.70	1.70
	Total Tax Expenses (a+b+c)	**0.81**	**5.27**	**5.45**	**37.54**
6	**Net Profit & Loss after Tax for the period (4-5)**	**3.22**	**14.77**	**11.64**	**107.04**
7	**Other Comprehensive Income, Net on Income Tax**				
	a) i) Items that will not be reclassified to profit or loss	-	-	(0.98)	(0.98)
	ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	1.20	1.20
	b) i) Items that will be reclassified to profit or loss	-	-	-	-
	ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Total other comprehensive income, net of income tax	**-**	**-**	**0.22**	**0.22**
8	**Total comprehensive income after tax (6+7)**	**3.22**	**14.77**	**11.86**	**107.26**
9	Paid-up Equity Share Capital (Face Value of Rs 10/- each)	219.28	219.28	219.28	219.28
10	Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year	519.76	434.43	434.43	434.43
11	Earnings Per Share (EPS) (Rs.) (not annualised)				
a)	Basic EPS	**0.15**	**0.67**	**0.53**	**4.88**
b)	Diluted EPS	**0.15**	**0.67**	**0.53**	**4.88**

Notes

1) The above Unaudited Financial Results were reviewed by the Audit Committee and approved by Board of Directors at their respective meetings held on 13th August, 2026

2) The Company is engaged in the business of "Trading of diagnostic medical consumables & electronic consumables, servicing of medical equipments & machines" and, therefore, has only one reportable segment in accordance with Ind AS 108 "Operating Segments".

3) Figures for the previous period have been recast / regrouped / rearranged, wherever necessary, to conform to the current period's classification.

4) The above results have been prepared in compliance with the recognition and measurement principles of the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) Amendment Rules, 2016 prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and relevant amendment rules thereafter.

5) These Results are also updated on the company's website URL: http://www.adsdiagnosticltd.com

For A D S DIAGNSOTIC LIMITED

Dr. Gautam Sehgal
Managing Director
DIN 00034243

Place : New Delhi
Date : 13th August 2026

ADS Diagnostic Limited
114, Sant Nagar East of Kailash New Delhi-110065

ADS DIAGNOSTIC LIMITED
114, SANT NAGAR, EAST OF KAILASH, NEW DELHI -110065
TEL.: 011-41622193, 41620434, FAX.: 011-41665880, : 07290037529, E-mail: adsmedical@rediffmail.com
CIN-: L85110DL1984PLC018486, Udyam Registration Number (MSME) - UDYAM-DL-08-0007361

V.N. PUROHIT & CO.
CHARTERED ACCOUNTANTS
INDIA

214, New Delhi House,
27, Barakhamba Road,
New Delhi - 110001
Ph: +91 11 43596011;
Email: delhi@vnp.in;
Web: http://www.vnp.in

INDEPENDENT AUDITOR'S REVIEW REPORT ON THE QUARTERLY UNAUDITED FINANCIAL RESULTS

To Board of Directors of
A D S Diagnostic Limited
114, Sant Nagar, East of Kailash,
New Delhi - 110065
(CIN: L85110DL1984PLC018486)

We have reviewed the accompanying statement of unaudited financial results (the "Statement") of **M/s. A D S Diagnostic Limited** (the "Company") for the quarter ended on **30th June, 2026**, being submitted by the Company pursuant to requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This statement which is the responsibility of the Company's Management has been approved by the Board of Directors has been prepared according to the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR V. N. PUROHIT & CO.
Chartered Accountants
Firm Regn. 304040E

Om Prakash Pareek
Digitally signed by Om Prakash Pareek
Date: 2026.08.13 12:40:09 +05'30'

O. P. Pareek
Partner
Membership No. 014238
UDIN: 26014238NMXXUV8539

New Delhi, the 13th day of August, 2026